Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.

ABSTRACT:

Introduction

Thyroid-associated ophthalmopathy (TAO) is a disfiguring, potentially blinding, and sub-optimally managed autoimmune condition. Current therapy of active TAO consists most frequently of glucocorticoid steroids, orbital radiation, or B-cell depletion; all of which are associated with substantial side effects. Teprotumumab (Tepezza) is a human monoclonal antibody against the insulin-like growth factor type I receptor (IGF-IR), recently evaluated in two clinical trials for active moderate-to-severe TAO that was recently approved by the United States Food and Drug Administration (FDA) for use in TAO.

Areas covered

This article reviews phase II and III placebo-controlled, double-masked, prospective, multicenter studies assessing the efficacy and safety of teprotumuma

SUBMITTER: Slentz DH 

PROVIDER: S-EPMC7529924 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature